MCID: END035
MIFTS: 42

Endocrine Gland Cancer

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Endocrine Gland Cancer

MalaCards integrated aliases for Endocrine Gland Cancer:

Name: Endocrine Gland Cancer 12 15
Malignant Neoplasm of Endocrine Gland 12 29 70
Endocrine Neoplasm 12 54 17
Endocrine Gland Neoplasms 44 70
Malignant Tumour of Endocrine Gland 12
Neoplasm of the Endocrine System 29
Neoplasm of Endocrine System 12
Carcinoma of Endocrine Gland 70
Neoplasm of Endocrine Gland 12
Malignant Endocrine Tumor 12
Endocrine Tumor 12

Classifications:



External Ids:

Disease Ontology 12 DOID:170
ICD9CM 34 194.9
MeSH 44 D004701
NCIt 50 C3010 C3575
SNOMED-CT 67 127015005 93780007
ICD10 32 C75.9
UMLS 70 C0014132 C0153658 C1704374

Summaries for Endocrine Gland Cancer

Disease Ontology : 12 An organ system cancer located in endocrine system that is characterized by uncontrolled cellular proliferation of the hormone producing glands of the endocrine system.

MalaCards based summary : Endocrine Gland Cancer, also known as malignant neoplasm of endocrine gland, is related to non-functioning pancreatic endocrine tumor and neuroendocrine tumor. An important gene associated with Endocrine Gland Cancer is MIR199A1 (MicroRNA 199a-1), and among its related pathways/superpathways are MicroRNAs in cancer and Cell Differentiation - Index. The drugs Dexlansoprazole and Lansoprazole have been mentioned in the context of this disorder. Affiliated tissues include endocrine system, thyroid and pituitary.

Related Diseases for Endocrine Gland Cancer

Diseases related to Endocrine Gland Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 457)
# Related Disease Score Top Affiliating Genes
1 non-functioning pancreatic endocrine tumor 33.2 SST GAST CHGA
2 neuroendocrine tumor 32.7 SYP SST RET GAST CHGA
3 thyroid gland cancer 32.7 SYP SST RET MIR9-1 MIR221 MIR17
4 pancreatic cancer 32.7 SST SERPINA3 RET MIR483 MIR34A MIR30A
5 adrenal carcinoma 32.7 SYP SST MIR483 CHGA
6 islet cell tumor 32.7 SYP SST SERPINA3 RET MIR483 GAST
7 pancreatic cholera 32.5 SST GAST CHGA
8 vipoma 32.5 SST GAST CHGA
9 multiple endocrine neoplasia 31.4 SST RET GNAS GAST CHGA
10 multiple endocrine neoplasia, type i 31.3 SYP SST RET MIR483 H2AC18 GNAS
11 thyroid gland medullary carcinoma 31.2 SYP SST RET MIR9-1 GAST CHGA
12 thyroid carcinoma, familial medullary 31.2 SST RET GAST CHGA
13 carcinoid syndrome 31.1 SYP SST CHGA
14 gastrinoma 30.9 SST GAST CHGA
15 cystadenoma 30.9 SYP SERPINA3 GNAS CHGA
16 small cell carcinoma 30.9 SYP GAST CHGA
17 neuroendocrine carcinoma 30.9 SYP SST GAST CHGA
18 cystadenocarcinoma 30.9 SERPINA3 MIR30A MIR199A1
19 renal cell carcinoma, nonpapillary 30.9 RET MIR9-1 MIR34A MIR30A MIR221 MIR214
20 zollinger-ellison syndrome 30.9 SST GAST CHGA
21 atrophic gastritis 30.9 SST GAST CHGA
22 ovarian serous cystadenocarcinoma 30.9 SERPINA3 MIR30A MIR17 GNAS
23 pancreatic endocrine carcinoma 30.8 SYP SST SERPINA3 GAST CHGA
24 in situ carcinoma 30.8 SERPINA3 MIR17 H2AC18
25 parathyroid adenoma 30.8 RET GNAS CHGA
26 carney complex variant 30.8 SST RET MIR483 GNAS
27 paraganglioma 30.8 SYP SST RET CHGA
28 papillary carcinoma 30.8 SYP RET CHGA
29 breast cancer 30.8 SYP SERPINA3 RET MIR9-1 MIR34A MIR30A
30 adenoma 30.7 SYP SST RET GNAS CHGA
31 pancreatic gastrinoma 30.7 SYP SST GAST CHGA
32 microcystic adenoma 30.7 SYP SERPINA3 MIR21 CHGA
33 glucagonoma 30.7 SST GAST CHGA
34 pancreatic ductal adenocarcinoma 30.7 MIR483 MIR30A MIR221 MIR21 MIR199A1 MIR196A1
35 leukemia, acute myeloid 30.7 SERPINA3 MIR9-1 MIR483 MIR34A MIR30A MIR221
36 pernicious anemia 30.7 SST GAST CHGA
37 autoimmune atrophic gastritis 30.7 GAST CHGA
38 pituitary adenoma, prolactin-secreting 30.7 SST GNAS CHGA
39 carcinoid tumors, intestinal 30.6 SYP SST GAST CHGA
40 small cell cancer of the lung 30.6 SYP SST MIR21 GAST CHGA
41 thyroid gland disease 30.6 SST SERPINA3 RET MIR9-1 MIR221 MIR199A1
42 ampulla of vater benign neoplasm 30.6 SYP SST CHGA
43 neuroblastoma 30.6 SYP SST RET MIR34A MIR221 MIR21
44 suppression of tumorigenicity 12 30.6 SYP SERPINA3 MIR199A1 H2AC18 CHGA
45 adrenal cortical carcinoma 30.6 SYP MIR483 MIR214 GNAS CHGA
46 somatostatinoma 30.6 SST GAST CHGA
47 intestinal disease 30.6 SERPINA3 MIR9-1 MIR483 MIR34A MIR30A MIR221
48 glioma 30.5 MIR34A MIR221 MIR21 MIR17
49 multiple endocrine neoplasia, type iia 30.5 SYP RET CHGA
50 ovarian cancer 30.5 MIR9-1 MIR34A MIR30A MIR221 MIR214 MIR21

Graphical network of the top 20 diseases related to Endocrine Gland Cancer:



Diseases related to Endocrine Gland Cancer

Symptoms & Phenotypes for Endocrine Gland Cancer

Drugs & Therapeutics for Endocrine Gland Cancer

Drugs for Endocrine Gland Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 133)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
2
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
3
Octreotide Approved, Investigational Phase 4 83150-76-9 383414 6400441
4 Antacids Phase 4
5 Anti-Ulcer Agents Phase 4
6 Proton Pump Inhibitors Phase 4
7 Gastrointestinal Agents Phase 4
8 Antineoplastic Agents, Hormonal Phase 4
9
lanreotide Approved Phase 3 108736-35-2
10
Somatostatin Approved, Investigational Phase 3 51110-01-1, 38916-34-6 53481605
11
Pancrelipase Approved, Investigational Phase 3 53608-75-6
12
Gemcitabine Approved Phase 3 95058-81-4 60750
13 Angiopeptin Phase 3
14 Liver Extracts Phase 2, Phase 3
15 Antimetabolites Phase 3
16 Antimitotic Agents Phase 3
17 Tubulin Modulators Phase 3
18 pancreatin Phase 3
19 Immunosuppressive Agents Phase 3
20 Immunologic Factors Phase 3
21 Anti-Infective Agents Phase 3
22 Antiviral Agents Phase 3
23 Immunoglobulins Phase 3
24 Antibodies Phase 3
25 Antibodies, Monoclonal Phase 3
26
Metformin Approved Phase 2 657-24-9 14219 4091
27
Ethiodized oil Approved, Investigational Phase 2 8008-53-5
28
Denosumab Approved Phase 2 615258-40-7
29
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
30
Levoleucovorin Approved, Investigational Phase 2 68538-85-2 149436
31
leucovorin Approved Phase 2 58-05-9 6006
32
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
33
Capecitabine Approved, Investigational Phase 1, Phase 2 154361-50-9 60953
34
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
35
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
36
Niraparib Approved, Investigational Phase 2 1038915-60-4 24958200
37
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
38
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
39
Mesna Approved, Investigational Phase 2 3375-50-6 598
40
Pembrolizumab Approved Phase 2 1374853-91-4
41
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
42
Aldesleukin Approved Phase 2 110942-02-4, 85898-30-2
43
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177 70789204
44
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
45
Fluorouracil Approved Phase 2 51-21-8 3385
46
Ondansetron Approved Phase 2 99614-02-5 4595
47
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
48
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
49
Bevacizumab Approved, Investigational Phase 2 216974-75-3
50
Streptozocin Approved, Investigational Phase 2 18883-66-4 29327

Interventional clinical trials:

(show top 50) (show all 80)
# Name Status NCT ID Phase Drugs
1 Clinical Effectiveness of Serum Chromogranin A (CgA) Levels on Diagnostic Relevance, Response After Surgical Resection and Recurrence of Pancreatic Endocrine Tumors (PET) Unknown status NCT02759718 Phase 4
2 Long-Term Study of the Efficacy and Safety of Lansoprazole in the Treatment of Zollinger-Ellison and Other Acid Hypersecretors Completed NCT00204373 Phase 4 Lansoprazole (Prevacid)
3 Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation A Prospective Interventional Trial of Patients With Neuro-endocrine Tumors With Carcinoid Syndrome Receiving Octreotide LAR Terminated NCT04140409 Phase 4 Sandostatin
4 Pasireotide Treatment for Insulin Producing Pancreatic Neuro-endocrine Tumor Withdrawn NCT02779257 Phase 4 Pasireotide;Diazoxide
5 Phase III, Randomised, Double-blind, Stratified Comparative, Placebo Controlled, Parallel Group, Multi-centre Study to Assess the Effect of Deep Subcutaneous Injections of Lanreotide Autogel 120mg Administered Every 28 Days on Tumour Progression Free Survival in Patients With Non-functioning Entero-pancreatic Endocrine Tumour Completed NCT00353496 Phase 3 lanreotide (Autogel formulation);Placebo
6 Open Label Extension Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero-pancreatic Endocrine Tumour Completed NCT00842348 Phase 3 lanreotide (Autogel formulation)
7 Intra-arterial Lutetium-177-dotatate for Treatment of Patients With Neuro-endocrine Tumor Liver Metastases Recruiting NCT03590119 Phase 2, Phase 3 Lutetium Lu 177-DOTATATE
8 A Phase 3, Multicenter, Open-label, Randomized Study of Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects With Surgically Resected Pancreatic Adenocarcinoma Active, not recruiting NCT01964430 Phase 3 nab-Paclitaxel;Gemcitabine
9 Correlation Between SUV on 68Ga-DOTATATE PET/CT and Ki-67 Index in Neuro-Endocrine Tumors Enrolling by invitation NCT02840149 Phase 3 68Ga-DOTATATE PET/CT
10 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Trial of AMG 479 or Placebo in Combination With Gemcitabine as First Line Therapy for Metastatic Adenocarcinoma of the Pancreas Terminated NCT01231347 Phase 3 AMG 479;Placebo;AMG 479;gemcitabine
11 Activity and Safety of Everolimus in Combination With Octreotide LAR and Metformin in Patients With Advanced Pancreatic Well-differentiated Neuroendocrine Tumors (pWDNETs): a Phase II, Open, Monocentric, Prospective Study Unknown status NCT02294006 Phase 2 Everolimus plus Octreotide LAR plus Metformin
12 A Single Arm, Multicenter Single Stage Phase II Trial of RAD001 as Monotherapy in the Treatment of Metastatic Non Syndromic Neuro-endocrine Tumors Completed NCT00688623 Phase 2 Everolimus
13 Everolimus as Treatment After Embolization or Chemoembolization for Liver Metastases From Digestive Endocrine Tumors Completed NCT01678664 Phase 2 Everolimus;Doxorubicin
14 An Open Label Study to Evaluate the Effect of Avastin in Association With Chemotherapy on Progression-free Survival in Patients With Progressive Advanced/Metastatic Well-differentiated Digestive Endocrine Tumors of the Gastrointestinal Tract Completed NCT00448136 Phase 2 bevacizumab [Avastin];5 FU;Streptozotocin;Xeloda
15 Phase I/II Trial of Vandetanib (ZD6474, ZACTIMA) in Children and Adolescents With Hereditary Medullary Thyroid Carcinoma Completed NCT00514046 Phase 1, Phase 2 Vandetanib
16 A Single-arm, Multicenter, Proof-of-concept Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium Despite Recent Treatment With IV Bisphosphonates Completed NCT00896454 Phase 2 denosumab
17 Efficacy and Safety of High Dose Regimen of Octreotide LAR in Patients With Neuroendocrine Tumors in Progressive Disease: A Phase II, Open, Multicentric Prospective Study Completed NCT00990535 Phase 2 Octreotide-LAR
18 A Phase 2 Study of GW786034 (Pazopanib) in Advanced Low-Grade or Intermediate-Grade Neuroendocrine Carcinoma Completed NCT00454363 Phase 2 Pazopanib Hydrochloride
19 Perfusion CT as Predictive Biomarker in a Phase II Study of Ziv-Aflibercept in Patients With Advanced Pancreatic Neuroendocrine Tumors Completed NCT02101918 Phase 2
20 Phase 2 Study of Efficacy and Safety of Trabectedin in Subjects With Advanced Ovarian Cancer Completed NCT00050414 Phase 2 Trabectedin;Dexamethasone
21 Study of First-Line Therapy Comprising Leucovorin Calcium, Fluorouracil, and Irinotecan (FOLFIRI) in Patients With Progressive Locally Advanced or Metastatic Duodenal-Pancreatic Endocrine Tumors Completed NCT00416767 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
22 Exploratory Basket Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. CABATEN Study Recruiting NCT04400474 Phase 2 Cabozantinib 40 mg
23 Efficacy of the Oncoxin-Viusid® Nutritional Supplement on the Quality of Life of Patients With Advanced or Metastatic Ovarian Epithelial Cancer. Clinical Trial Phase II. Recruiting NCT03562897 Phase 2
24 Evaluation of the Effect of Ocoxin-Viusid® Nutritional Supplement in the Life Quality in Patients Diagnosed With Advanced Pancreatic Adenocarcinoma. Phase II Recruiting NCT03717298 Phase 2
25 A Phase I/II Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan (GAX-CI) in Combination in Metastatic Pancreatic Cancer Recruiting NCT03535727 Phase 1, Phase 2 Nab-paclitaxel;Gemcitabine;Capecitabine;Cisplatin;Irinotecan;Nab-paclitaxel;Gemcitabine;Capecitabine;Cisplatin;Irinotecan
26 A Single-arm, Prospective, Open-label, Phase II Study to Evaluate the Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer Recruiting NCT04556071 Phase 2 Niraparib;Bevacizumab
27 A Phase II Study of Lenvatinib in Combination With Everolimus in Patients With Advanced Carcinoid Tumors Recruiting NCT03950609 Phase 2 Everolimus;Lenvatinib
28 A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors Recruiting NCT03037385 Phase 1, Phase 2 pralsetinib (BLU-667)
29 Phase II Study of Sorafenib (BAY 43-9006) in Patients With Metastatic Medullary Thyroid Carcinoma Active, not recruiting NCT00390325 Phase 2 Sorafenib Tosylate
30 A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Suspended NCT03412877 Phase 2 Cyclophosphamide;Fludarabine;Aldesleukin;Pembrolizumab (KEYTRUDA )
31 Phase II Study of Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors Terminated NCT00609765 Phase 2 Avastin;Fluorouracil;Doxorubicin;Streptozocin;Dexamethasone;Ondansetron
32 A Multicenter Phase II Open Study Coupled With a Translational Assessment of Biomarkers Predictive of Response to Sunitinib in Patients With Poorly-differentiated Advanced/Inoperable NEURO-Endocrine Tumors. Terminated NCT01215578 Phase 2 Sutent
33 Drug- Drug Interaction Study of JI-101 & Everolimus in Advanced Solid Tumors, Expansion Pharmacodynamic Study of JI-101 in Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers Terminated NCT01149434 Phase 1, Phase 2 JI-101;Everolimus
34 A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors Terminated NCT00947167 Phase 2 pertuzumab;erlotinib
35 Treatment of a Cancerous Disease of the Peritoneum With Complete Cytoreductive Surgery With Intraperitoneal Chemohyperthermia Using Oxaliplatin Plus Irinotecan Terminated NCT00180960 Phase 2 Oxaliplatin and irinotecan
36 A Phase 1, Randomized, Open-Label, Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors (SNDX-275-0141, MK3475-460/KEYNOTE-460) Unknown status NCT02909452 Phase 1 Entinostat;Pembrolizumab
37 A Phase 1 Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors Completed NCT02897778 Phase 1 Entinostat
38 A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other Indications Recruiting NCT01552434 Phase 1 Temsirolimus;Valproic Acid
39 Ex-Vivo Expanded Allogeneic NK Cells for the Treatment of Solid Tumors of Pediatric Origin in Children and Young Adults Recruiting NCT03420963 Phase 1 Cyclophosphamide;Etoposide
40 A Phase 1 Study of Veliparib (ABT-888) in Combination With Capecitabine and Temozolomide in Advanced Well-Differentiated Neuroendocrine Tumors Withdrawn NCT02831179 Phase 1 Capecitabine;Temozolomide;Veliparib
41 Type 1 Multiple Endocrine Neoplasia : a Cohort Study of the Endocrine Tumor Study Group (GTE) Unknown status NCT03262129
42 A Single Centre Analysis of Clinical Characteristics and Treatment of Endocrine Pancreatic Tumours. Completed NCT02400996
43 Development of an Innovative Gallium 68 Radiolabeling of DOTATOC (68Ga-DOTATOC) for PET-CT Imaging of Neuro-endocrine Tumors and Preliminary Clinical Evaluation Completed NCT02134639
44 Psychosocial Aspects of Multiple Endocrine Neoplasia (MEN) Syndromes Completed NCT00501449
45 Feasibility of Activity Monitoring in Patients With Cancer: Physical Activity Monitoring in Cancer Patients (PAMCap) Completed NCT02583815
46 Study of Molecular Pathways in Medullary Thyroid Carcinoma (MTC) and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients Completed NCT01424878
47 Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours. Completed NCT01398306
48 B-Receptor Signaling in Cardiomyopathy Completed NCT01135849
49 Assessing the Patient Experience in Cancer Care: An Observational Communication Study Completed NCT01621295
50 Efficacy and Safety of Radiofrequency Ablation Under Endoscopic Ultrasonography Guidance in Pancreatic Neuroendocrine and Cystic Tumor Completed NCT02330497

Search NIH Clinical Center for Endocrine Gland Cancer

Cochrane evidence based reviews: endocrine gland neoplasms

Genetic Tests for Endocrine Gland Cancer

Genetic tests related to Endocrine Gland Cancer:

# Genetic test Affiliating Genes
1 Malignant Neoplasm of Endocrine Gland 29
2 Neoplasm of the Endocrine System 29

Anatomical Context for Endocrine Gland Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Endocrine Gland Cancer:

19
Endocrine System

MalaCards organs/tissues related to Endocrine Gland Cancer:

40
Thyroid, Pituitary, Bone, Pancreas, Lung, Breast, Heart

Publications for Endocrine Gland Cancer

Articles related to Endocrine Gland Cancer:

(show all 16)
# Title Authors PMID Year
1
[The role of molecular testing in thyroid tumors]. 61
33351337 2020
2
Loss of E-cadherin and cytoplasmic-nuclear expression of beta-catenin are the most useful immunoprofiles in the diagnosis of solid-pseudopapillary neoplasm of the pancreas. 54
17959228 2008
3
A sensitive mutation-specific screening technique for GNAS1 mutations in cases of fibrous dysplasia: the first report of a codon 227 mutation in bone. 54
17493233 2007
4
RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. 54
16029119 2005
5
Met proto-oncogene and insulin-like growth factor binding protein 3 overexpression correlates with metastatic ability in well-differentiated pancreatic endocrine neoplasms. 54
15448002 2004
6
Prognostic value of hMLH1 methylation and microsatellite instability in pancreatic endocrine neoplasms. 54
14668721 2003
7
Amylin in pancreatic islets and pancreatic endocrine neoplasms. 54
14507315 2003
8
Familial and second lung cancers: a nation-wide epidemiologic study from Sweden. 61
12609563 2003
9
Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: correlation with microvessel density and clinicopathologic features. 54
12605362 2003
10
Pulmonary gangliocytic paraganglioma: case report and comparative immunohistochemical study of related neuroendocrine neoplasms. 54
11342785 2001
11
Clear cell endocrine pancreatic tumor mimicking renal cell carcinoma: a distinctive neoplasm of von Hippel-Lindau disease. 54
11342771 2001
12
Clinical implications of genetic defects in G proteins: oncogenic mutations in G alpha s as the molecular basis for the McCune-Albright syndrome. 54
10714367 1999
13
Mutation of RET proto-oncogene in Japanese patients with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. 54
9447290 1997
14
Immunohistochemical localization of acidic fibroblast growth factor in normal human enterochromaffin cells and related gastrointestinal tumours. 54
9083514 1997
15
Endocrine gland cancer. 61
8001005 1995
16
Molecular approaches for the analysis of chromogranins and secretogranins. 54
1342950 1992

Variations for Endocrine Gland Cancer

Expression for Endocrine Gland Cancer

Search GEO for disease gene expression data for Endocrine Gland Cancer.

Pathways for Endocrine Gland Cancer

Pathways related to Endocrine Gland Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.85 MIR9-1 MIR483 MIR34A MIR30A MIR221 MIR214
2 10.71 MIR9-1 MIR221 MIR199A1

GO Terms for Endocrine Gland Cancer

Cellular components related to Endocrine Gland Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.81 SERPINA3 MIR9-1 MIR34A MIR21 MIR17 MIR125A
2 extracellular space GO:0005615 9.7 SST SERPINA3 MIR30A MIR221 MIR21 MIR199A1
3 extracellular vesicle GO:1903561 9.23 MIR34A MIR30A MIR221 MIR214 MIR21 MIR17

Biological processes related to Endocrine Gland Cancer according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.97 SST MIR9-1 MIR221 MIR214 MIR21
2 negative regulation of gene expression GO:0010629 9.91 MIR34A MIR214 MIR21 MIR17 MIR125A
3 positive regulation of protein kinase B signaling GO:0051897 9.86 RET MIR221 MIR21 MIR199A1
4 negative regulation of cell migration GO:0030336 9.83 MIR9-1 MIR34A MIR214 MIR21
5 negative regulation of angiogenesis GO:0016525 9.78 MIR34A MIR214 MIR21 MIR125A
6 negative regulation of sprouting angiogenesis GO:1903671 9.67 MIR34A MIR221 MIR17
7 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.62 MIR221 MIR214 MIR21 MIR17
8 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.61 MIR34A MIR214 MIR21
9 negative regulation of cytokine-mediated signaling pathway GO:0001960 9.6 MIR21 MIR125A
10 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.59 MIR221 MIR125A
11 positive regulation of metalloendopeptidase activity GO:1904685 9.58 MIR21 MIR17
12 positive regulation of connective tissue replacement GO:1905205 9.58 MIR34A MIR214 MIR199A1
13 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.57 MIR21 MIR17
14 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.56 MIR483 MIR221 MIR199A1 MIR196A1
15 negative regulation of lamellipodium assembly GO:0010593 9.55 MIR214 MIR196A1
16 miRNA mediated inhibition of translation GO:0035278 9.55 MIR9-1 MIR483 MIR221 MIR21 MIR17
17 negative regulation of interleukin-21 production GO:0032705 9.54 MIR221 MIR21
18 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.54 MIR214 MIR199A1 MIR17
19 positive regulation of vascular smooth muscle cell dedifferentiation GO:1905176 9.46 MIR221 MIR214
20 gene silencing by miRNA GO:0035195 9.4 MIR9-1 MIR483 MIR34A MIR30A MIR221 MIR214
21 negative regulation of vascular endothelial growth factor production GO:1904046 9.26 MIR34A MIR199A1 MIR17 MIR125A

Molecular functions related to Endocrine Gland Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.43 MIR9-1 MIR34A MIR30A MIR21 MIR17 MIR125A
2 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.36 MIR9-1 MIR483 MIR34A MIR30A MIR221 MIR214

Sources for Endocrine Gland Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....